The preoperative kinetics of prostate-specific antigen as a predict of relapse-free survival after radical prostatectomy
https://doi.org/10.17650/1726-9776-2014-10-4-47-51
Abstract
Objectivе. The purpose of the study – to estimate the prognostic value of preoperative prostate-specific antigen (PSA) doubling time (PSADT) in patients with prostate cancer (PCa) after radical prostatectomy (RP).
Materials and Methods. The preoperative PSADT was determined in 92 patients with PCa who underwent RP in FSBI RRCRST. Incidence of biochemical recurrence and adverse pathologic features after surgery (positive lymph nodes and surgical margins, locally advanced and poorly differentiated tumors) were estimate according to the level of preoperative PSADT.
Results. The correlation between the preoperative PSA kinetics and postoperative pathological findings after radical prostatectomy was shown. Positive lymph nodes (p = 0.04), locally advanced (p = 0.03) and poorly differentiated tumors (p = 0.046) were significantly more frequent in patients with a PSADT ≤ 20,0 months. The role of preoperative PSADT as a predict of relapse-free survival after radical prostatectomy was confirmed. By multivariate analysis preoperative PSADT ≤ 20 months showed a statistically significant increase in the relative risk of biochemical recurrence.
About the Authors
O. A. Bogomolov
FSBI «Russian Research Center for Radiology and Surgical Technologies», Ministry of Health of Russia, 68, Leningradskaya St., Pesochnyi Settlement, Saint Petersburg 197758
Russian Federation
Russian Federation
M. I. Shkolnik
FSBI «Russian Research Center for Radiology and Surgical Technologies», Ministry of Health of Russia, 68, Leningradskaya St., Pesochnyi Settlement, Saint Petersburg 197758
Russian Federation
Russian Federation
G. M. Zharinov
FSBI «Russian Research Center for Radiology and Surgical Technologies», Ministry of Health of Russia, 68, Leningradskaya St., Pesochnyi Settlement, Saint Petersburg 197758
Russian Federation
Russian Federation
References
1. Magklara A., Scorilas A., Stephan C. et al. Decreased concentrations of prostate-specific antigen and human glandular kallikrein 2 in malignant versus nonmalignant prostatic tissue. Urology 2000;56:527–32.
2. Saleh A. Role of prostate specific antigen (PSA) in pathogenesis of prostate cancer. J of Cancer Therapy 2012;3:331–6.
3. Williams S.A., Singh P., Isaacs J.T., Denmeade S.R. Does PSA play a role as a promoting agent during the initiation and/or progression of prostate cancer. Prostate 2007;67(3):312–29.
4. Pandey R., Patil N., Rao M. Proteases and Protease Inhibitors: implications in antitumorogenesis and drug development. Int J Human Genetics 2007; 7(1): 67–82.
5. Sutkowski D.M., Goode R.L., Banial J. et al. Growth regulation of prostatic stromal cells by prostate-specific antigen. J Natl Cancer Inst 1999; 91(19):1663–9.
6. Veveris-Lowe T.L., Lawrence M.G., Collard R.L. et al. Kallikrein 4 (hK4) and prostate-specific antigen (PSA) are associated with the loss of E-cadherin and an epithelial-mesenchymal transition (EMT)-like effect in prostate cancer cells. Endocrine-Related Cancer 2005;12:631–43.
7. Lin J.T., Wang J.S., Jiann B.P. et al. Correlation of p53 protein accumulation and Bcl-2 overexpression with histopathological features in prostatic cancer. J Formosan Med Association 2005;104(11): 864–7.
8. Wang L.G., Liu X.M., Kreis W., Budman D.R. through inhibition of complex formation between androgen receptor and steroid receptor binding consensus in the promoter of the PSA gene in LNCaP cells. Cancer Res 1997; 57(4):714–9.
9. Iwamura M., Hellman J., Cockett A.T. et al. Alteration of the hormonal bioactivity of parathyroid hormone-related protein (PTHrP) as a result of limited proteolysis by prostatespecific antigen. Urology 1996;48:317–25.
10. Heidenreich A., Bolla M., Joniau S. et al. Members of the European Association of Urology (EAU) Guidelines Office. Guidelines on Prostate Cancer. In: EAU Guidelines, edition presented at the 25th EAU Annual Congress, Barcelona 2010.
11. Ramirez M.L., Nelson E.C., Devere R.W. et al. Current applications for prostate-specific antigen doubling time. Eur Urol 2008;54(2):291–300.
12. Hanks G.E., Hanlon A.L., Lee W.R. et al. Pretreatment prostate-specific antigen doubling times: clinical utility of this predictor of prostate cancer behavior. Int J Radiat Oncol Biol Phys 1996;34:549–53.
13. Goluboff E.T., Heitjan D.F., DeVries G.M. et al. Pretreatment prostate specific antigen doubling times: use in patients before radical prostatectomy. J Urol 1997;158:1876–8.
14. Egawa S., Arai Y., Tobisu K. et al. Use of pretreatment prostate-specific antigen doubling time to predict outcome after radical prostatectomy. Prostate Cancer Prostatic Dis 2000;3:269–74.
15. Freedland S.J., Dorey F., Aronson W.J. Preoperative PSA velocity and doubling time do not predict adverse pathologic features or biochemical recurrence after radical prostatectomy. Urology 2001;57: 476–80.
16. Memorial Sloan-Kettering Cancer Center cancer information: prostate nomogram. http://www.mskcc.org/mskcc/html/10088.cfm.
Review
For citations:
Bogomolov O.A., Shkolnik M.I., Zharinov G.M. The preoperative kinetics of prostate-specific antigen as a predict of relapse-free survival after radical prostatectomy. Cancer Urology. 2014;10(4):47-51. (In Russ.) https://doi.org/10.17650/1726-9776-2014-10-4-47-51
Views:
874
Email this article 